Connect with us

Medical Cannabis

New Study Suggests THC and CBD Could Help Treat Agitation in Dementia Patients

Published

on

New Study Suggests THC and CBD Could Help Treat Agitation in Dementia Patients

A formulation of THC and CBD significantly reduced agitation among patients with end-stage dementia in a first-of-its-kind clinical trial, MedicalXpress reports.

The multicenter, randomized, double-blind, placebo-controlled Phase II study (known as the LiBBY trial, for the recent benefits of cannabidiol and tetrahydrocannabinol) included 120 hospice-eligible participants with Alzheimer’s disease or other types of dementia they were experiencing. The findings were presented July 14 at the Alzheimer’s Association International Conference in London by researchers from the Medical University of South Carolina and Georgetown University.

Participants received either a placebo or a fast-acting oil suspension containing isolated THC and CBD. After two weeks, patients in the THC/CBD group showed a significantly greater reduction in mean agitation scores than the placebo group. The researchers said the improvement was maintained at 12 weeks.

A secondary analysis also found that 83.9% of patients in the THC/CBD group were rated as significantly less anxious after two weeks, compared to 30.5% in the placebo group. At 12 weeks, 87.2% of treatment group participants showed improvement, compared to 23.6% of placebo participants.

“Rarely do we see close to 90% of patients in a trial who respond positively to a new drug,” said Jacobo Mintzer, MD, of the Medical University of South Carolina and co-investigator of the study.

While the findings are promising, the researchers also noted that the treatment was a precisely formulated medical product administered under clinical supervision and may differ significantly from commercially available cannabis products.

Ganjapreneur: Providing everyday knowledge since 2014, the leading digital business magazine for cannabis industry professionals. to join our community of over 40,000 weedpreneurs.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

cannabis policy

Wyoming Drugs Commissioner Will Not Reschedule Cannabis Under State Law Despite Federal Reforms 

Published

on

By

Wyoming Drugs Commissioner Will Not Reschedule Cannabis Under State Law Despite Federal Reforms 

The Wyoming Attorney General’s Office said the state will not reschedule cannabis under state law, regardless federal reforms the movement of medical cannabis from Schedule I to Schedule III under the Controlled Substances Act. In a policy statement released last week, the attorney general’s office said the state has already scheduled Food and Drug Administration (FDA)-approved pharmaceutical cannabis drugs — such as Dronabinol and Cesamet — as Schedule III and Schedule II drugs, respectively, and that Epidiolex has been completely removed from the state’s drug schedule.

The ruling states that state lawmakers have not legalized cannabis for any purpose in the state or recognized any other state’s medical cannabis licenses.

“Therefore, placing marijuana subject to a state medical marijuana license in Schedule III of the Wyoming Controlled Substances Act is inconsistent with the police powers heretofore exercised by the Wyoming Legislature. – Wyoming Attorney General’s Office, “Final Decision of the Commissioner of Drug and Substance Control Regarding the Placement of FDA-Approved Drug Products Containing Marijuana and Marijuana Under State License in Schedule III of the Wyoming Substances Act,” 7/7/26

The announcement adds that during a hearing in June regarding potential state rescheduling of cannabis, eight comments were received from the Drug and Substance Abuse Commissioner. Comments were evenly split between maintaining the status quo and rescheduling cannabis in Schedule III.

The order states that the commissioner “shall appropriately schedule products approved by the (FDA) after that agency has approved the product.”

Ganjapreneur: Providing everyday knowledge since 2014, the leading digital business magazine for cannabis industry professionals. to join our community of over 40,000 cannabis entrepreneurs.

TG joined Ganjapreneur in 2014 as a news writer and began hosting the Ganjapreneur podcast in 2016. He is based in upstate New York, where he also teaches media at a local university.

Continue Reading

adult use

Kansas Governor Candidate Pushes Cannabis Legalization Platform

Published

on

By

Kansas Governor Candidate Pushes Cannabis Legalization Platform

The Democratic front-runner for governor of Kansas is calling for the legalization of medical and adult cannabis in the state. In one video posted on Facebook from the parking lot of a dispensary in Missouri — just across the state line from her Johnson County home, state Sen. Cindy Holscher noted that the place was “full of Kansas license plates.”

“That’s a lot of Kansas tax dollars going straight into Missouri’s pocket. Most Kansas voters think marijuana should be legal in our state, but because it’s not Kansas, we buy it out of state and we miss the opportunity to raise more money for schools and public services.” — Holscher in a video posted to Facebook

Holscher noted that last year Missouri collected $255 million in tax dollars from cannabis sales in the state.

“This is real money that can make a big difference for Kansans,” Holscher said in the video. “Legalization means we will build an industry in Kansas of farmers and small businesses and keep our tax dollars in the state to benefit our schools.”

Holscher added that legalizing cannabis is “common sense” and that adults should be allowed to consume cannabis “safely and responsibly”.

or last survey by Change Research, commissioned by Civic Clarity, which operates the Capitol Bee news entity, found Holscher with 37% support among poll respondents, while Johnson County state Sen. Ethan Corson received 10% support and Overland Park Mayor Curt Skoog at 7%.

or Kansas Speaks Poll published in February found that 70% of Kansans support the legalization of medical cannabis, while 60% support adult-use reforms.

Ganjapreneur: Providing everyday knowledge since 2014, the leading digital business magazine for cannabis industry professionals. to join our community of over 40,000 cannabis entrepreneurs.

Continue Reading

Education

More Than 85% of U.S. Healthcare Professionals Believe Cannabis Has Medical Utility

Published

on

By

More Than 85% of U.S. Healthcare Professionals Believe Cannabis Has Medical Utility

According to survey data published in Journal of Cannabis Research.

The anonymous, web-based survey involved 879 health care professionals, most of whom reported that they had already encountered cannabis use among their patients. Eighty-nine percent of respondents said they had patients who use cannabis, while 87% said they believe cannabis has therapeutic promise. Ninety-five percent said they support the legal use of medical cannabis, and 74% said they would be open to recommending medical cannabis to patients.

The survey group included mental health professionals, registered nurses, physicians, and advanced practice providers. Respondents rated their knowledge of cannabis higher for its risks and therapeutic indications, but the researchers found much lower scores when participants were tested on objective knowledge of cannabis-related risks, therapeutic uses, and mechanisms of action.

The most common sources of knowledge about cannabis were personal experience and popular media, cited by 76% and 73% of respondents, respectively. The researchers also found that fewer respondents had received structured clinical training on cannabis, although many expressed openness to using it in practice.

The most cited concerns about the clinical use of cannabis included a lack of trained providers, potential exploitation of patients, recreational misuse, and the risk of psychosis. Greater openness to the clinical use of cannabis was associated with higher knowledge of self-esteem, younger age, professional role, and less worry.

The study authors said the findings indicate a need for structured training on cannabis pharmacology, dosing, contraindications, and legal and ethical considerations, as well as better systems for monitoring the use of cannabis in patient care.

NORML Deputy Director Paul Armentano said the findings reflect the growing acceptance of medical cannabis among healthcare providers.

“The use and efficacy of medical cannabis is now widely accepted by health care professionals,” said Armentano. in a statement. “As more doctors, nurses and others integrate medical cannabis into their clinical practices, it is vital that medical associations, institutions and educational curricula alike include and embrace cannabis as a mainstream and established therapeutic option for patients.”

discovery are consistent with a 2021 study published in Cannabis and cannabinoid researchwhich found that nearly 69% of more than 2,200 US clinicians believed that cannabis has medical benefits. In that survey, 27% of respondents said they had prescribed cannabis to a patient, while 60% incorrectly identified their state’s cannabis legalization policy.

Ganjapreneur: Providing everyday knowledge since 2014, the leading digital business magazine for cannabis industry professionals. to join our community of over 40,000 cannabis entrepreneurs.

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media